Appendix cancer differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 27: | Line 27: | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan="2" rowspan="5" |Diseases | ! colspan="2" rowspan="5" |Diseases | ||
| colspan=" | | colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
| colspan=" | | colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
! colspan=" | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
Line 45: | Line 42: | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in bowel habits | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in bowel habits | ||
! rowspan="2" |'''Other symptoms''' | ! rowspan="2" |'''Other symptoms''' | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal mass | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal mass | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |abdominal tenderness | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |abdominal tenderness | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other physical examination findings | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Urinary 5-hydroxyindoleacetic acid (5-HIAA)''' | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Urinary 5-hydroxyindoleacetic acid (5-HIAA)''' | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Serum Chromogranin A (CgA)''' | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Serum Chromogranin A (CgA)''' | ||
Line 64: | Line 56: | ||
!Diarrhea | !Diarrhea | ||
!Constipation | !Constipation | ||
|- | |- | ||
| rowspan="3" |Appendix cancer | | rowspan="3" |Appendix cancer | ||
Line 71: | Line 62: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| | | | ||
Line 79: | Line 67: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 107: | Line 93: | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |Flushing | ||
Palpitation | |||
Dyspnea | |||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Tricuspid regurgitation | |||
* murmur | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
Line 133: | Line 121: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| | | | ||
Line 141: | Line 126: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 155: | Line 138: | ||
|- | |- | ||
| colspan="2" |Mucocele | | colspan="2" |Mucocele | ||
| | | | ||
| | | | ||
Line 180: | Line 158: | ||
|- | |- | ||
| colspan="2" |Ovarian tumor | | colspan="2" |Ovarian tumor | ||
| | | | ||
| | | | ||
Line 205: | Line 178: | ||
|- | |- | ||
| colspan="2" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma peritonei]] | | colspan="2" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma peritonei]] | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
| | | | ||
| | | | ||
|Shifting dullness | |||
| | | | ||
| | | | ||
| | | | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | | | ||
| | | | ||
Line 230: | Line 198: | ||
|- | |- | ||
| colspan="2" |Carcinoid syndrome | | colspan="2" |Carcinoid syndrome | ||
|<nowiki>-/+</nowiki> | |||
|<nowiki>-</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>-</nowiki> | |||
|Flushing | |||
Palpitation | |||
Dyspnea | |||
|<nowiki>-</nowiki> | |||
|<nowiki>-</nowiki> | |||
| | | | ||
* Tricuspid regurgitation | |||
* murmur | |||
* Wheezing | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
| | | | ||
* Ki67 | |||
* N-terminal pro–B-type natriuretic peptide | |||
* [[Substance P]] | |||
* [[Neurotensin]] | |||
* [[Bradykinin]] | |||
* [[Human chorionic gonadotropin]] | |||
* Neuropeptide L | |||
* [[Pancreatic polypeptide]] | |||
|Depends on the primary tumor location and type | |||
|Depends on the primary tumor location and type | |||
|Depends on the primary tumor location and type | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 261: | Line 240: | ||
* Secretory type | * Secretory type | ||
| <nowiki>+</nowiki> | | <nowiki>+</nowiki> | ||
| | |[[Nausea and vomiting|Nausea & vomiting]],[[decreased appetite]] | ||
Anorexia | |||
Tachycardia is prevalent | Tachycardia is prevalent | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | | | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 294: | Line 262: | ||
|CT scan | |CT scan | ||
|[[Appendicitis diagnostic scoring|Alvarado Score]] | |[[Appendicitis diagnostic scoring|Alvarado Score]] | ||
|- | |- | ||
| | | | ||
Line 326: | Line 268: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| | | | ||
Line 334: | Line 273: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 352: | Line 289: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| | | | ||
Line 360: | Line 294: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 378: | Line 310: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| | | | ||
Line 386: | Line 315: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 19:20, 8 February 2019
Appendix cancer Microchapters |
Diagnosis |
---|
Treatment |
Appendix cancer differential diagnosis On the Web |
American Roentgen Ray Society Images of Appendix cancer differential diagnosis |
Risk calculators and risk factors for Appendix cancer differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
appendix cancer must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
appendix cancer must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating appendix cancer from other Diseases
appendix cancer must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
appendix cancer must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
OR
As appendix cancer manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Differentiating appendix cancer from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], appendix cancer must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||||
Abdominal pain | Change in girdle size | Change in bowel habits | Other symptoms | Abdominal mass | abdominal tenderness | Other physical examination findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) | Serum Chromogranin A (CgA) | Other lab findings | CT scan | MRI | Utrasounography | Other imaging modalities | ||||||
Diarrhea | Constipation | ||||||||||||||||||
Appendix cancer | Adenocarcinoma |
|
|
||||||||||||||||
Carcinoid tumor | +/- | - | + | - | Flushing
Palpitation Dyspnea |
- | - |
|
+ | + |
|
|
Histopathology | ||||||
Mucocele | |||||||||||||||||||
Ovarian tumor | |||||||||||||||||||
Pseudomyxoma peritonei | + | + | Shifting dullness | - | - | ||||||||||||||
Carcinoid syndrome | -/+ | - | + | - | Flushing
Palpitation Dyspnea |
- | - |
|
+ | + |
|
Depends on the primary tumor location and type | Depends on the primary tumor location and type | Depends on the primary tumor location and type | |||||
Appendicitis | LLQ / RRQ | - | -/+
|
+ | Nausea & vomiting,decreased appetite
Anorexia Tachycardia is prevalent |
+/- | + | - | - |
|
Appendiceal wall thickening /perforation
peri-appendiceal inflammation, fluid accumulation,fat stranding |
Increased fluid signal on T2 weighted sequence | Evidences of inflammation | Tc-99m labeled anti-CD15 antibodies | Evidences of inflammation | CT scan | Alvarado Score | ||
Differential Diagnosis 4 | |||||||||||||||||||
Differential Diagnosis 5 | |||||||||||||||||||
Differential Diagnosis 6 |